Literature DB >> 27922481

PD-L1 Assessment for Targeted Therapy Testing in Cancer: Urgent Need For Realistic Economic and Practice Expectations.

Hadi Yaziji1, Clive R Taylor.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27922481      PMCID： PMC5144920          DOI： 10.1097/PAI.0000000000000472

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN： 1533-4058


× No keyword cloud information.
  8 in total

Review 1.  Non-Small Cell Lung Cancer, PD-L1, and the Pathologist.

Authors:  Keith M Kerr; Marianne C Nicolson
Journal:  Arch Pathol Lab Med       Date:  2016-03       Impact factor: 5.534

2.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

Authors:  Roy S Herbst; Paul Baas; Dong-Wan Kim; Enriqueta Felip; José L Pérez-Gracia; Ji-Youn Han; Julian Molina; Joo-Hang Kim; Catherine Dubos Arvis; Myung-Ju Ahn; Margarita Majem; Mary J Fidler; Gilberto de Castro; Marcelo Garrido; Gregory M Lubiniecki; Yue Shentu; Ellie Im; Marisa Dolled-Filhart; Edward B Garon
Journal:  Lancet       Date:  2015-12-19       Impact factor: 79.321

3.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

Authors:  Julie R Brahmer; Scott S Tykodi; Laura Q M Chow; Wen-Jen Hwu; Suzanne L Topalian; Patrick Hwu; Charles G Drake; Luis H Camacho; John Kauh; Kunle Odunsi; Henry C Pitot; Omid Hamid; Shailender Bhatia; Renato Martins; Keith Eaton; Shuming Chen; Theresa M Salay; Suresh Alaparthy; Joseph F Grosso; Alan J Korman; Susan M Parker; Shruti Agrawal; Stacie M Goldberg; Drew M Pardoll; Ashok Gupta; Jon M Wigginton
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

Review 4.  Practicing pathology in the era of big data and personalized medicine.

Authors:  Jiang Gu; Clive R Taylor
Journal:  Appl Immunohistochem Mol Morphol       Date:  2014-01

5.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Authors:  Neal I Lindeman; Philip T Cagle; Mary Beth Beasley; Dhananjay Arun Chitale; Sanja Dacic; Giuseppe Giaccone; Robert Brian Jenkins; David J Kwiatkowski; Juan-Sebastian Saldivar; Jeremy Squire; Erik Thunnissen; Marc Ladanyi
Journal:  J Mol Diagn       Date:  2013-04-04       Impact factor: 5.568

6.  Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer.

Authors:  Therese Phillips; Pauline Simmons; Hector D Inzunza; John Cogswell; James Novotny; Clive Taylor; Xiaoling Zhang
Journal:  Appl Immunohistochem Mol Morphol       Date:  2015-09

7.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; David G Hicks; Mitch Dowsett; Lisa M McShane; Kimberly H Allison; Donald C Allred; John M S Bartlett; Michael Bilous; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Pamela B Mangu; Soonmyung Paik; Edith A Perez; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

8.  A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1.

Authors:  Patricia Gaule; James W Smithy; Maria Toki; Jamaal Rehman; Farah Patell-Socha; Delphine Cougot; Philippe Collin; Paul Morrill; Veronique Neumeister; David L Rimm
Journal:  JAMA Oncol       Date:  2017-02-01       Impact factor: 31.777
  8 in total
  1 in total

1.  Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models.

Authors:  Roberto R Rosato; Daniel Dávila-González; Dong Soon Choi; Wei Qian; Wen Chen; Anthony J Kozielski; Helen Wong; Bhuvanesh Dave; Jenny C Chang
Journal:  Breast Cancer Res       Date:  2018-09-05       Impact factor: 6.466
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.